Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMAB819 vs Nivolumab in Recurrent/Metastatic HNSCC
NCT04659369Phase 1Terminated
- Sponsor
- Taizhou Mabtech Pharmaceutical
- Start
- Sep 2020
- Primary completion
- Oct 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of CMAB819 in squamous cell carcinoma of the head and neck (HNSCC) (2 arms), sponsored by Taizhou Mabtech Pharmaceutical. Primary endpoint: Area Under the Curve from Day 1 to Day 29. Started Sep 2020; status: terminated.
02
Drugs
CMAB819
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT04659369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04659369.